First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.
carcinoma
hepatocellular
nonalcoholic steatohepatitis
sequential therapy
sorafenib
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
04
10
2021
received:
09
09
2021
accepted:
06
10
2021
pubmed:
26
10
2021
medline:
23
3
2022
entrez:
25
10
2021
Statut:
ppublish
Résumé
Sequential therapy with molecular-targeted agents (MTAs) is considered effective for unresectable hepatocellular carcinoma (HCC) patients. This study purposed to evaluate the efficacy of sequential therapy with sorafenib (SORA) as a first-line therapy and to investigate the therapeutic impact of SORA in nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steato hepatitis (NASH)-related HCC. We evaluated 504 HCC patients treated with SORA (Study-1). The times of administration for sorafenib from 2009 to 2015, 2016 to 2017, and 2018 and later were defined as the early-, mid-, and late-term periods, respectively. Among them, 180 HCC patients treated with SORA in addition to MTAs in the mid- and late-term periods were divided into groups based on disease etiology (NAFLD or NASH [n = 37] and viral or alcohol [n = 143]), and outcomes were compared after inverse probability weighting (IPW) (Study-2). Overall survival (OS) of HCC patients who received sequential MTA therapy after first-line SORA was significantly longer. The median survival times (MST) were 12.6 versus 17.6 versus 17.4 months in the early-term group, mid-term group, and the later-time group (early vs. mid, p = 0.014, early vs. later. p = 0.045), respectively. (Study-1). In Study-2, there was no significant differences in OS between the Virus/alcohol group and the NAFLD/NASH group in patients who received sequential therapy (MST was 23.4 and 27.0 months p = 0.173, respectively). The NAFLD or NASH, female sex, albumin-bilirubin (ALBI) grade 2b, and major Vp (Vp3/Vp4) were significant factors for OS treated with SORA. Sequential therapy with SORA as the first-line treatment improved the prognosis of unresectable HCC patients and was effective regardless of HCC etiology.
Sections du résumé
BACKGROUND AND AIMS
Sequential therapy with molecular-targeted agents (MTAs) is considered effective for unresectable hepatocellular carcinoma (HCC) patients. This study purposed to evaluate the efficacy of sequential therapy with sorafenib (SORA) as a first-line therapy and to investigate the therapeutic impact of SORA in nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steato hepatitis (NASH)-related HCC.
METHODS
We evaluated 504 HCC patients treated with SORA (Study-1). The times of administration for sorafenib from 2009 to 2015, 2016 to 2017, and 2018 and later were defined as the early-, mid-, and late-term periods, respectively. Among them, 180 HCC patients treated with SORA in addition to MTAs in the mid- and late-term periods were divided into groups based on disease etiology (NAFLD or NASH [n = 37] and viral or alcohol [n = 143]), and outcomes were compared after inverse probability weighting (IPW) (Study-2).
RESULTS
Overall survival (OS) of HCC patients who received sequential MTA therapy after first-line SORA was significantly longer. The median survival times (MST) were 12.6 versus 17.6 versus 17.4 months in the early-term group, mid-term group, and the later-time group (early vs. mid, p = 0.014, early vs. later. p = 0.045), respectively. (Study-1). In Study-2, there was no significant differences in OS between the Virus/alcohol group and the NAFLD/NASH group in patients who received sequential therapy (MST was 23.4 and 27.0 months p = 0.173, respectively). The NAFLD or NASH, female sex, albumin-bilirubin (ALBI) grade 2b, and major Vp (Vp3/Vp4) were significant factors for OS treated with SORA.
CONCLUSIONS
Sequential therapy with SORA as the first-line treatment improved the prognosis of unresectable HCC patients and was effective regardless of HCC etiology.
Identifiants
pubmed: 34693661
doi: 10.1002/cam4.4367
pmc: PMC8633265
doi:
Substances chimiques
Antineoplastic Agents
0
Sorafenib
9ZOQ3TZI87
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
8530-8541Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Liver Cancer. 2020 Jan;9(1):73-83
pubmed: 32071911
Target Oncol. 2021 May;16(3):401-410
pubmed: 33646487
Cancer Med. 2021 Dec;10(23):8530-8541
pubmed: 34693661
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
J Hepatol. 2018 Jul;69(1):154-181
pubmed: 29628280
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
J Hepatol. 2019 Apr;70(4):817
pubmed: 30739718
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
BMC Gastroenterol. 2014 May 03;14:84
pubmed: 24886354
Indian J Gastroenterol. 2017 Sep;36(5):373-379
pubmed: 28975595
Invest New Drugs. 2020 Feb;38(1):172-180
pubmed: 31172442
Liver Cancer. 2019 Oct;8(5):312-325
pubmed: 31768342
Hepatology. 2011 Dec;54(6):2055-63
pubmed: 21898496
J Hepatol. 2017 Nov;67(5):999-1008
pubmed: 28687477
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Hepatol Res. 2015 May;45(5):548-59
pubmed: 24976563
Invest New Drugs. 2015 Dec;33(6):1257-62
pubmed: 26462681
Gastroenterology. 2015 Mar;148(3):547-55
pubmed: 25461851
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Invest New Drugs. 2021 Feb;39(1):260-268
pubmed: 32749658
Ann Oncol. 2013 Feb;24(2):406-411
pubmed: 23041587
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
J Gastroenterol Hepatol. 2021 Mar;36(3):629-636
pubmed: 32627871
Nature. 2021 Apr;592(7854):450-456
pubmed: 33762733
NCHS Data Brief. 2018 Jul;(314):1-8
pubmed: 30044212
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Hepatol Res. 2020 Dec;50(12):1375-1385
pubmed: 32924266
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Sci Rep. 2021 Aug 17;11(1):16663
pubmed: 34404856
Stat Med. 2005 Oct 30;24(20):3089-110
pubmed: 16189810
Gastroenterology. 2012 Jun;142(7):1592-609
pubmed: 22656328
Invest New Drugs. 2019 Jun;37(3):567-572
pubmed: 30523474